Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients with Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, but Still Complaining of Excessive Daytime Sleepiness

Trial Profile

Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients with Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, but Still Complaining of Excessive Daytime Sleepiness

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Pitolisant (Primary)
  • Indications Hypersomnia
  • Focus Therapeutic Use
  • Acronyms HAROSA III
  • Sponsors Bioprojet
  • Most Recent Events

    • 02 Dec 2016 Last checked against the ClinicalTrials.gov record.
    • 29 Nov 2016 Status changed from recruiting to completed.
    • 06 Jun 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top